References
- Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoeconomics Outcomes Res.10(6), 707–722 (2010).
- Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol.1(141), 1–16 (2011).
- Duerden M. Making sense of drug pricing. In: Prescriber Supplement 1–5. John Wiley & Sons Ltd, Chichester, UK (2006).
- Chaplin S, Duerdin M. When Brands are Best: Brand vs. Generic Prescribing: Prescriber Guide. Wiley Interface Ltd, NJ, USA (2006).
- McGinn D, Godman B, Lonsdale J et al. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK; impact and implications. Expert Rev. Pharmacoeconomics Outcomes Res.10(1), 73–85 (2010).
- Kanavos P. Do generics offer significant savings to the UK national health service? Curr. Med. Res. Opin.23, 105–116 (2007).
- Godman B, Shrank W, Wettermark B et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals3, 2470–2494 (2010).
- Smith PC, York N. Quality incentives: the case of UK general practioners. Health Affairs23, 112–118 (2004).
- Doran T, Fullwood C, Gravelle H et al. Pay-for-performance programs in family practices in the United Kingdom. N. Engl. J. Med.355, 375–384 (2006).
- Collins R, Armitage J, Parish S et al. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet361, 2005–2016 (2003).
- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology and the European Association for the Study of Diabetes. Eur. Heart J.28, 88–136 (2007).
- Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26, 91–98 (2008).
- Norman C, Zarrinkoub R, Hasselström J et al. Potential savings without compromising the quality of care. Int. J. Clin. Pract.63, 1320–1326 (2009).
- Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract.62, 480–484 (2008).
- Hjemdahl P, Allhammar A, Heaton C et al. SBU should investigate what is an evidencebased and cost-effective use of statins. Läkartidningen32, 1992–1994 (2009).
- Feely J, Bennett K. Epidemiology and economics of statin use. Ir. Med. J.101, 188–191 (2008).
- Vončina L, Strizrep T, Godman B et al. Influence of prescribing restrictions compared with other demand side measures to enhance renin–angiotensin prescribing efficiency: implications for other countries. Expert Rev. Pharmacoeconomics Outcomes Res.11, 469–479 (2011).
- Gustafsson LL, Wettermark B, Godman B et al. The ‘wise list’ – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol.108, 224–233 (2011).
- Moon J, Flett A, Godman B, Grosso A, Wierzbicki A. Getting better value from the NHS drug budget. BMJ342, 30–32 (2011).
- Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking – an overview of current approaches and their consequences. Appl. Health Econ. Health Policy7, 137–147 (2009).
- Duerden M, Miller J, Godman B et al. Centralised guidance – how NICE and SIGN impact on care in the UK. In: Bausteine Für Ein Neues Gesundheitswesen. Klusen N, Straub C (Eds). Nomos Verlagsgesellschaft, Baden-Baden, Germany, 51–61 (2003).
Websites
- Office of Fair Trading (UK). The pharmaceutical price regulation system: an OFT study. Annexe A: market for prescription pharmaceuticals in the NHS. The Office of Fair Trading, London, UK (2007). www.oft.gov.uk/shared_oft/reports/comp_policy/oft885a.pdf (Accessed 10 November 2011)
- NHS Department of Health. Quality and outcomes framework guidance – updated August 2004. www.dh.gov.uk/en/healthcare/primarycare/primarycarecontracting/QOF/DH_4125653 (Accessed 10 November 2011)
- SIGN. Heart disease – quick reference guide. February 2007. www.sign.ac.uk/pdf/qrgchd.pdf (Accessed 13 November 2011)
- Lothian prescribing bulletin. Generic uptake – significant savings for Lothian (April/May 2003). www.ljf.scot.nhs.uk/prescribingbulletins/2003/lpb/LPB%20Issue%20No%202.pdf (Accessed 13 November 2011)
- SIGN. Management of diabetes – quick reference guide. March 2010. www.sign.ac.uk/pdf/qrg116.pdf (Accessed 13 November 2011)
- World Health Organization. Introduction to drug utilisation research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330). http://apps.who.int/medicinedocs/en/d/Js4876e/ (Accessed 10 November 2011)
- Lothian prescribing bulletin. Generic omeprazole first choice PPI. April/May 2004. www.ljf.scot.nhs.uk/prescribingbulletins/2004/prescribing%20bulletins/lothian%20precribing%20bulletin%20No%208%20Apr-%20May%202004.pdf (Accessed 10 November 2011)
- Audit Scotland. Supporting prescribing in general practice – a progress report. June 2003. www.audit-scotland.gov.uk/docs/health/2003/nr_030626_supporting_prescribing_km.pdf (Accessed 10 November 2011)
- Lothian prescribing bulletin. Assessing cardiovascular disease risk – new treatment thresholds for prevention. April/ May 2005. www.ljf.scot.nhs.uk/prescribingbulletins/2005/lpb/LPB%20Issue%20No%2014.pdf (Accessed 10 November 2011)
- SIGN. Dyspepsia – a national clinical guideline. March 2003. www.sign.ac.uk/pdf/sign68.pdf (Accessed 10 November 2011)
- SIGN. Secondary prevention of CHD following myocardial infarction. A national clinical guideline (2000). www.nhsggc.org.uk/content/mediaassets/pdf/HSD/sign41.pdf (Accessed 13 November 2011)